02:01:07 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Marapharm Ventures Inc
Symbol MDM
Shares Issued 75,616,923
Recent Sedar Documents

ORIGINAL: Marapharm added to U.S. Marijuana Index

2017-04-18 19:40 ET - News Release

Received by email:

File: NR.April.18.2017.NT.docx

News Release       April 18, 2017

Marapharm Ventures Inc. "Marapharm" announces it's been added to the United States Marijuana Index

Marapharm has been added (source: forbes.com) to the United States Marijuana Index (marijuanaindex.com). The North Ame
--->rican Marijuana Index, composed from the United States Marijuana Index and the Canadian Marijuana Index, tracks the le
--->ading cannabis stocks listed on North American stock exchanges. The North American Marijuana Index level in April 2016
---> was 50 and in April 2017 the index level is 150, an increase of approximately 200%. In order for a company to be in t
--->he Index the criteria includes having a weighted average minimum market daily trading volume of $600,000.
 
A stock market index is a measurement of the value of a section of the stock market. It is computed from the prices of
---> selected stocks. It is a tool used by investors and financial managers to describe the market and to compare the retu
--->rn of specific investments. 

"Marapharm is pleased to be part of this important index which is the voice of credibility for the rapid development o
--->f the marijuana sector. We are executing on our plans, by bringing the Nevada facility into production, capitalizing o
--->n the real estate acquisition in Washington, have property and permits in California and will continue to look for add
--->itional opportunities for cultivation and production licenses and facilities in the United States. In addition, our in
--->vestment in Veritas Pharma continues to provide synergy and our investment has more than doubled in value within 3 mon
--->ths
"Linda Sampson, Marapharm CEO.

ABOUT MARAPHARM VENTURES INC.
www.marapharm.com 

Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly tr
--->aded in Canada, under the ticker symbol "MDM" on the Canadian Securities Exchange, and in the United States, under the
---> ticker symbol "MRPHF" on the OTCQB, and in Europe, under the ticker symbol "2M0" on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two an
--->d a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has pas
--->sed the necessary security clearances. The application is currently in the in-depth screening process. In September 20
--->16, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMP
--->R.

Additional information on the operations or financial results of Marapharm are included in reports on file with applic
--->able securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (
--->www.otcmarkets.com), and the SEDAR website (www.sedar.com) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION: 
www.marapharm.com  or Linda Sampson, CEO, 778-583-4476 email info@marapharm.com

STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQBtrademark has approved nor disapproved the contents of this press release. Neith
--->er the CSE, the FSE nor the OTCQBtrademark accepts responsibility for the adequacy or accuracy of this release.



FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "
--->anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions 
--->are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties a
--->nd other factors that may cause actual results or events to differ materially from those anticipated in such forward-l
--->ooking statements are based on reasonable assumption but no assurance can be given that these expectations will prove 
--->to be correct and the forward-looking statements included in this news release should not be unduly relied upon.




© 2024 Canjex Publishing Ltd. All rights reserved.